Continuous Manufacturing Under ICH Q13
ICH Q13 addresses continuous manufacturing (CM) — a mode of production where material moves through the process without the discrete stops that define a traditional batch — covering both processes designed as continuous from the start and existing batch processes converted to continuous operation. Adopted at Step 4 on 16 November 2022, it was ICH’s first guideline written specifically around this manufacturing mode rather than assuming batch processing as the default.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 19 LINKSContinuous manufacturing forces a definition rather than a technology decision: with no discrete steps, a site must say what a batch is, how material is traced through it, and what happens to product made while the process was diverting.
06 · QUALITY MATURITY — CONTINUOUS MANUFACTURING UNDER ICH Q13, REACTIVE TO ADAPTIVE
Continuous equipment is operated as a faster batch line. Batch definition, traceability and diversion handling were never restated for it.
A batch definition exists and diversion logic is configured, but residence time distribution is a vendor figure rather than a measured property of this process.
Residence time distribution is determined experimentally, material traceability follows from it, and diversion decisions are tied to the disturbance they respond to.
Run length, start-up and shut-down are characterised as states with their own controls, and state-of-control is judged over time rather than at a sampling point.
The system detects and corrects disturbance before diversion is needed, and process understanding is deep enough that batch definition can be varied deliberately rather than fixed by caution.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 1 regulatory body: ICH.
RECORDS & OBJECTIVE EVIDENCE
- The batch definition, and the material traceability model that follows from it
- Residence time distribution determination for this equipment and this formulation
- Diversion logic with the disturbances it responds to and the disposition of diverted material
- Start-up, shut-down and steady-state characterisation, including qualified run lengths
- Process monitoring data demonstrating a maintained state of control across a full run
COMMON INSPECTION FINDINGS
- A batch defined by convenience with no traceability model connecting input material to output units
- Residence time taken from the equipment vendor rather than measured for the actual process
- Diverted material dispositioned without a record linking it to the disturbance that caused diversion
- Start-up and shut-down excluded from validation while product from those states was released
- Run length extended in routine operation beyond what the validation data covers
Redefining “Batch” Without Discrete Steps
Traditional GMP batch definitions assume a discrete mixing or blending event that establishes homogeneity across a defined quantity of material. A continuous process has no such single event, so Q13 introduces the concept of defining a batch through time-based or quantity-based criteria applied to a continuous run — a definitional shift with real consequences for batch release, deviation scope, and recall boundaries.
Control Strategy Elements Unique to CM
A continuous-manufacturing control strategy needs to address material traceability through the process (so a specific input lot can be linked to the output material it became), residence time distribution (understanding how long material actually spends in each unit operation, since this varies rather than resetting between discrete batches), and a defined mechanism for diverting nonconforming material in real time without halting the entire run.
Dependence on Process Analytical Technology
Continuous processes are difficult to control without in-line or on-line measurement, because there is no natural pause point to pull a representative discrete sample the way a batch process allows. Q13-compliant control strategies accordingly lean heavily on the process-analytical-technology and real-time-release concepts already established under ICH Q8 and EU GMP Annex 17, applied continuously rather than at a single release checkpoint.
Converting an Existing Batch Process
Q13 explicitly covers the case of converting an already-approved batch process to continuous manufacturing, and expects the comparability logic familiar from other post-approval change frameworks — demonstrating the converted process delivers product of equivalent quality, not simply that the new equipment runs.
Diversion, State of Control and Changes in Output
Q13 expects the control strategy to detect and divert potentially non-conforming material during production — for example at start-up, shutdown or during a disturbance — using an understanding of residence time distribution and process dynamics to trace input materials through the system, with criteria to start and end diversion and to restart collection (section 3.1.6). It defines a state of control for continuous processes as parameters changing within specified ranges, not necessarily a steady state, and asks manufacturers to detect drift or trends within those ranges and find their root cause, such as input variation, equipment fatigue or resin ageing (3.1.1). It names in-line UV, near-infrared and on-line HPLC as examples of PAT well suited to continuous processes (3.1.5).
Because output can be changed by running longer, increasing mass flow or scaling out, Q13 lists the new risks each route can introduce — over longer run times, for example, process drift, material build-up, sensor fouling and microbial contamination — and asks for the approach to be justified and the control strategy updated (3.2). A quantitative metric for batch-to-batch consistency is defined in the quality system, such as diverted material relative to collected material (4.3). Converting an approved batch process requires a new control strategy, comparable output quality established by a science- and risk-based approach, and regulatory approval before implementation (4.6). Process validation may use a fixed number of batches or continuous process verification (4.7).
FREQUENTLY ASKED
How is a “batch” defined in continuous manufacturing?
Q13 applies the ICH Q7 definition of a batch to all modes of continuous manufacturing and says batch size can be defined by the quantity of output material, the quantity of input material, or run time at a defined mass flow rate; other approaches are possible if scientifically justified, and a batch size can be defined as a range, for example by a minimum and maximum run time (section 2.2).
Can an existing approved batch process be converted to continuous manufacturing?
Yes — Q13 explicitly addresses this scenario, and expects the manufacturer to demonstrate the converted process produces product of equivalent quality, following comparability-style reasoning.
Why does continuous manufacturing rely so heavily on PAT?
Without a natural discrete pause point for sampling, real-time in-line or on-line measurement is generally the only practical way to confirm product quality throughout an ongoing run.
Does Q13 apply to both drug substance and drug product manufacturing?
Yes — Q13 covers continuous manufacturing of both drug substances and drug products, and of the combined, integrated processes some CM implementations use.
Does converting an approved batch process to continuous manufacturing need regulatory approval?
Yes. ICH Q13 section 4.6 says manufacturers should seek regulatory approval before implementing a conversion of an approved batch process to continuous manufacturing, with comparable output quality established and the need for additional bioequivalence, non-clinical or clinical studies and stability data assessed on science and risk.
What examples of PAT does ICH Q13 give for continuous manufacturing?
Section 3.1.5 gives in-line UV flow cells to monitor therapeutic protein concentration, in-line near-infrared spectroscopy to assess blend uniformity or water content, and on-line HPLC to monitor conversion of a chemical reaction, noting that PAT allows disturbances to be detected in real time.
The inspection-readiness playbook for this topic
PUT THIS PLAYBOOK TO WORK
- HOW-TO GUIDEHow to Implement Real-Time Release Testing →Build an RTRT strategy that a regulator can approve and a site can run.
- TEMPLATEReal-Time Release Testing Strategy Plan →
A free account keeps what you save, remembers where you are across devices, and can send you the weekly regulatory briefing. Create a free account